Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mocertatug rezetecan plus bevacizumab versus platinum doublet plus bevacizumab in platinum-sensitive ovarian cancer
NL-OMON61778Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Nov 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of mocertatug rezetecan in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by GSK. Primary endpoint: Progression-free survival by BICR. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
mocertatug rezetecan
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NL-OMON61778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61778.